AMENDMENTS TO THE CLAIMS:

Amend the claims as follows:

Claims 1-44. (Canceled)

- 45. (Currently Amended) An isolated HCV antibody which specifically binds to specifically binding a type 3 HCV antigen selected from the group consisting of:
- (i) an antigen consisting of 5 or more contiguous amino acids selected from the region spanning positions 140 to 191 of the Core region of HCV type 3a, wherein the antigen contains at least one HCV genotype 3a-specific amino acid.
- 46. (Previously Presented) The HCV antibody according to claim 45 wherein said antigen is consisting of 5 or more contiguous amino acids selected from
- (i) the region spanning positions 140 to 191 of the Core region of HCV type 3a identified by SEQ ID NOs: 14, 16, 18, 20, 24,

wherein the antigen contains at least one HCV genotype 3a-specific amino acid.

- 47. (Previously Presented) The HCV antibody according to claim 45 which has been produced upon immunization of a mammal with any of said antigens.
- 48. (Previously Presented) The HCV antibody according to claim 45 which is a monoclonal antibody.

MAERTENS, et al. Appl. No. 09/899,046 September 14, 2005

- 49. (Previously Presented) A humanized version of an HCV antibody according to claim 48.
- 50. (Previously Presented) The humanized version of an HCV antibody according to claim 49 which has been humanized by means of recombinant DNA technology.
- 51. (Previously Presented) The HCV antibody according to claim 45 which further comprising a label.
- 52. (Previously Presented) The HCV antibody according to claim 51 wherein said label is of the enzymatic, fluorescent or radioactive type.
- 53. (Previously Presented) A composition comprising an HCV antibody according to claim 45.
- 54. (Previously Presented) A kit for determining the presence of HCV antigens present in a biological sample, said kit comprising:
 - (a) at least one HCV antibody according to claim 45,
- (b) a buffer enabling the binding reaction between an HCV antibody of (a) and an HCV antigen present in said biological sample; or components necessary for producing said buffer,
 - (c) a means for detecting the immune complexes formed between an HCV

MAERTENS, et al. Appl. No. 09/899,046 September 14, 2005

antibody of (a) and an HCV antigen present in said biological sample.

- 55. (Previously Presented) A kit for determining the presence of HCV antigens present in a biological sample, said kit comprising at least one HCV antibody according to claim 45.
- 56. (Withdrawn) A method for determining the presence of HCV antigens present in a biological sample, said method comprising the steps of:
- (a) contacting said biological sample with at least one HCV antibody according to claim 45,
 - (b) detecting the immune complexes formed in (a),
- (c) inferring from (b) the presence of said HCV antigens in said biological sample.